Could De Historia Kinger (Control University Conducts School of Medicinal Co. Tabulary Marcol Control University Republic Co. White Control and Only and PEX Product Facusina On View Chief and Control Control University Republic Co. White Control and Control Cont	8:50~9:00			
Search 2014 - Color Search 2014 - Color De Tauthoris Deput (Septiment Septiment				
Could De Historia Kinger (Control University Conducts School of Medicinal Co. Tabulary Marcol Control University Republic Co. White Control and Only and PEX Product Facusina On View Chief and Control Control University Republic Co. White Control and Control Cont	9:00~10:00			
Speaked Services On Floating Floating Properties De Van Kloster (Fold Herman Floating) Properties Alana Sessos 2 it Herman Floating of Marietal Editions of Parking United Medical College, Chanel Chair On Lang Klister (Herman Floating) Properties of the Special Properties De Van Lang Marieta (Link Medical College) De Van John Sey Klister, Michigan Channer Center Research Instituted On Vanisha Klister (Herman Floating) Properties (Herman Floating) De Van John Sey Klister, Michigan Channer Center Research Instituted On Vanisha Klister (Herman Floating) De Van John Sey Klister, Michigan Channer Center Research Instituted On Vanisha Klister (Herman Floating) De Van John Klister (Herman	9.00~10.00		ION EXTRIBUTION OF THE PROPERTY OF THE PROPERT	
Speaked D. A. Michael Total University, School of Medicine Development Discourant Development (PER Discourant Development) D. Wes-Other Close Obstation of Towns University Hospitals, Chaines Tappel Level Development of Discourant Development (PER Discourant Development) Development of Discourant Development (PER Discourant Development) Promptop of Michael Intelligent Close (PER Discourant Development) Development Discourant (PER Discourant Development) Development Discourant (PER Discourant Development) Development Development (PER Discourant Development) Development (PER Discourant D		Chair	Dr. Hitoshi Kiyoi (Nagoya University Graduate School of Medicine)	
Chart Microenterioring Company ESP General Expose D. Wen-China Chart Continued Training Continued Program of Profile in the Research State of Profile in the Researc			Dr. Takahiro Maeda (Kyushu University Hospital)	
D. Wen-Cheo Cheo (Poteros Pares) Fason University Fospata, Chinese Tappel The Cheo Cheo Cheo (Chinese Receiver of Medical Sciences & Pering Union Medical College, China) D. Tao Chinese (Chinese Receiver of Medical Sciences & Pering Union Medical College, China) Alain Session 2: Here Medical Lack and the China Chinese China (Chinese Receiver of Mass) D. Issay Kindsopal Receiver of Mass Sepater D. Lacy Kindsopal Receiver of Mass D. Issay Kindsopal China Chi		Speaker	Dr. Ai Kotani (Tokai University, School of Medicine)	
The Cilitate and Ecosphic Partners of HOPE is not have about a legislate. I exhausts a property of the Cilitate and Cilita				
Dr. Tan Change (Chinese Ancheroper of Medical Sciences A Private (Nation Statistics)				
Akina Session 2: Henotological Leukeris of Akin Akina Session 2: Henotological Leukeris of Akin Discussion 2: Henotological Leukeris of Akin Discussion 2: Henotological Leukeris of Akina Discussion 2: Henotological Leukeris Akina Discussion 2: Henotological Clarker Clarker Clarker (Leukeris) Speedur Discussion 2: Discussi				
Saint Securio 2. I Mentantiangical Leaders of Asia Onit 1. Sept. Sec. 1. Sec.				
Online District probabilists (Michael Career Center Records Institute)			Incompetence of Normal Hematopoiesis in Leukemia and Its Mechanisms	
Speaker Dr. Versichen, Versich Recht Michael (Service), China		Asian Sessi	ion 2 : Hematological Leaders of Asia	
Speaker Dr. Versichen, Versich Recht Michael (Service), China		Chair	Dr. Issav Kitabavashi (National Cancer Center Research Institute)	
Speeker D. Has Jineg (People's Hospita). Poling University Chinals (People's Hospita). Poling University Chinals and Addrashed and Addrashed in MDS-TII and AM1-198C Dr. Ashibits Yakopama (Matterial Canasa Centre) Transcription Makey in Medical Canasa Centre) Transcription Makey in Medical Canasa Centres (People's Canasa Centre) Transcription Makey in Medical Canasa Centres (People's Canasa Centre) (People's Canasa Cen		Onun		
Elicocy and Safety of Decidable in Combination with C-DEF, Law-dees Cytanobles and Advance in In MDS-EB and ANII-4/INC D D. Aktilists of Anisopania (Mational Cancer Central)		Cnookor	·	
D. A. Albibio Yakoyama (National Cancer Center) Transcription for National Authorises that Driver Authorises that		эреакег		
Transcriptoral Mechanism Prince (Inc.) - Recorded Legislation (I				
Do. You-Dis Kim (Sepol SLMPs y Hospital). The Carbolic University of Korea, Korea				
100-01-010 Finance France Franc				
Pleasing Session 1 : Epigenetic Abnormalities of Hematological Maliginancies, Basic Studies Child	10.00 10.10			
Chair On Talawand Technism (Mokalad University) On Hideo Harigas (Technic University) On Hideo Harigas (Technic University) On Hideo Harigas (Technic University) Speaker On Hideo Harigas (Technic University) Select of Two Domethylases for Histone (1982). MINOS and UTX, in Normal Hernatopolicis and Lukkenagenosis On Dealed Staryowards (Cincinnate Childeria) Hiosphall Medical Center : University of Cincinnat, USA) On Control Staryowards (Cincinnate Children's Hoopphall Medical Center : University of Cincinnat, USA) On Minos Kurokava (The University of Tokyo) Wards (2015) Habitah Hoopphal Hoopphall Medical Center : University of Cincinnat, USA) On Minos Kurokava (The University of Malmi Milito School of Medicine, USA) Episceneto Deropation in Aging and MISS Bayak 12-05-12-39 Chair On Kenichi Lahizawa (Yamagata University) David Medical Militoria Lumcheon Seminar I Co-Sponsored by Chagai Pharmacoutical Co., Ltd.) Chair On Shinoval Rid Ridagoy City University Graduata School of Medical Sciences Speaker Or, Irane M. Ghobrial (Harvard Medical School) Steven and Milchelle Kinch Laboratory: Dana-Farber Cancer Institute, USA) Multiple Mysolomo: Disease Medical School Steven and Milchelle Kinch Laboratory: Dana-Farber Cancer Institute, USA) Multiple Mysolomo: Disease Medical School Steven and Milchelle Kinch Laboratory: Dana-Farber Cancer Institute, USA) Multiple Mysolomo: Disease Medical School Steven and Milchelle Kinch Laboratory: Dana-Farber Cancer Institute, USA) Multiple Mysolomo: Disease Medical School Steven and Milchelle Kinch Laboratory: Dana-Farber Cancer Institute, USA) Multiple Mysolomo: Disease Medical School Steven and Milchelle Kinch Laboratory: Dana-Farber Cancer Institute, USA) Multiple Mysolomo: Disease Mysolo			nicav	
Speaker Dr. Hiroski Honds (Talpy Winner's Medical University) Or. Brinski Honds (Talpy Winner's Medical University) Or. Drain's Starceynoveki (Circlinati Children's Hoppital Medical Center : University of Circlinati, USA) Or. Brinski Starceynoveki (Circlinati Children's Hoppital Medical Center : University of Circlinati, USA) Or. Mines Kurokawa (The University of Tolypy) Or. Marie E. Figurenta University of Tolypy Or. Marie E. Figurenta University of Mismi Miller School of Medicine, USA) Eggenater Desregation in Aging and MOS Dr. Marie E. Figurenta University of Mismi Miller School of Medicine, USA) Eggenater Company of the Company of Company	10:10~11:50	Plenary Ses	ssion 1 : Epigenetic Abnormalities of Hematological Malignancies; Basic Studies	
Der Hicke Harings (Tehnbut University Graduate School of Medicine) Speaker De Historia National Chips Wissens Historia University Programme (Programme) De Dennis Starcaywowal (Cincinnati Children's Hospital Medical Center : University of Cincinnati, USA) Consequent Instruments Signifying and MSDs and AMI. De Mines Kurukawa (The University of Tokyo) Marine Kurukawa (The University of Tokyo) De Marine J. Figures University of Mismi Miller School of Medicine, USA) Eggrande Designation in Aging and MSDs Service Unicheon Seminar I (Co-Sponsored by Chagai Pharmacountical Co., Ltd.) Chair Or. Kenich Ishaizwa (Yamagasu University) De Kenich Ishaizwa (Yamagasu University) De Speaker De A Medick (Well Cornell Medicine, USA) Speaker Unicheon Seminar I (Co-Sponsored by Chagai Pharmacountical Co., Ltd.) Chair Or. Kenich Ishaizwa (Yamagasu University) De Speaker De A Medick (Well Cornell Medicine, USA) Speaker De A Medick (Well Cornell Medicine, USA) Speaker De A Medick (Well Cornell Medicine, USA) Speaker De Speaker De A Medick (Well Cornell Medicine, USA) Speaker Speaker De Speaker (So-Sponsored by Chagai Pharmacountical Co., Ltd.) Chair De Speaker (So-Sponsored by Chagai Pharmacountical Co., Ltd.) Chair De Speaker (So-Sponsored by Chagai Pharmacountical Co., Ltd.) Chair De Speaker (So-Sponsored by Chagai Pharmacountical Co., Ltd.) Chair De Speaker (So-Sponsored by Chagai Pharmacountical Co., Ltd.) Chair De Speaker (So-Sponsored by Chagai Pharmacountical Co., Ltd.) Chair De Speaker (So-Sponsored by Chagai Pharmacountical Co., Ltd.) Chair De Speaker (So-Sponsored by Chagai Pharmacountical Co., Ltd.) De Speaker (So-Sponsored By Chagai Pharmacountical Co., Ltd.) De Speaker (So-Sponsored By Chagai Pharmacountical School of Medicine) De Speaker (So-Sponsored By Chagai Pharmacountical School of Medicine) De Speaker (So-Sponsored By Chagai Pharmacountical School of Medicine) De Speaker (So-Sponsored By Chagai Pharmacountical School of Medicine) De Speaker (So-Sponsored By Chagai		Chair	Dr. Takanori Teshima (Hokkaido University)	
Speaker D. Handa's Honds CTalya Woman's Medical University Dubes of Two Demotorlystases for Histories 19527, MINDS and UTX, in Normal Hemistopinesis and Leukemogenesis Dr. Daniel Stancapynowski (Cincinnat Children's Hospital Medical Center : University of Cincinnat, USA) Dr. Openies Indicate Introduce Signaling in MIOS and AMI.				
Butes all Two Demethylaces for Histories HIRZP, IMADS and UTX, in Normal Hematopoissis and Leudemagnesis Dr. Daniel Starczynowski (Cincinnati Children's Hospital Medical Center : University of Cincinnati, USA) Dr. Millero Kurokawa (The University of Totyo) Mariel E. Figuerea (University of Totyo) Mariel E. Figuerea (University of Mismi Miller School of Medicine, USA) [Tippendic Deregations in Aging and MDS Dr. Mariel E. Figuerea (University of Mismi Miller School of Medicine, USA) [Tippendic Deregations in Aging and MDS Break Luncheon Seminar 1 (Co-Sponsored by Chugai Pharmaceutical Co., Ltd.) Chair Dr. Kantichi Inhizawa (Yamgata University) Speakor Dr. And Menick (Well Carnell Medicine, USA) Bilatory of Fillolated Impohane Luncheon Seminar 2 (Co-Sponsored by Celegine K.K.) Chair Dr. Shreak Hobbid (Mayor City University) Graduate School of Medical Scienceae) Speakor Dr. Inne M. Dehobid (Harvard Medical School : Steven and Michelle (Kirich Laboratory : Dana-Farber Cancer Institute, USA) Miller Myelmer. Disease Mechanism and Treatment Strategy 12:50-13:55 Poster Viewing Speakor Dr. Karsha (Model Carnell Collegion of Myelopodiferative Neoplasm (MPN) Chair Dr. Karsha (Mariel Children) Dr. Shirip Makasa (Kharsharou University) Denealated Polycomic Faunctoris in the Pathogenesis of Myelopodiferative Neoplasm Dr. Karsya (Stokal University Hospital Beaution) Dr. Shirip Makasa (Kharsharou Missersity) Denealated Polycomic Faunctoris in the Pathogenesis of Myelopodiferative Neoplasma Dr. Karsya (Stokal University Hospital Beaution) Dr. Shiry Makasa (Gharsharou Missersity) Denealated Polycomic Faunctoris in the Pathogenesis of Propodypos and Paranalary Productions Dr. Tory Carnell Myssersity (Missersity) Denealated Polycomic Faunctoris in the Pathogenesis of Propodypos and Paranalary Productions Dr. Tory Carnellos (Missersity of Cambridge, UK) Myelopodiferative Neoplasma From Pathogenesis of Propodypos and Paranalary Productions Dr. Tory Carlellos (Missersity of Cambridge, UK) Dr. Tory Carlellos (Missersi		Speaker		
D. Duniel Starczynowski (Cincinnati Children's Hospital Medical Center : University of Cincinnati, USA) Dr. Marios Kurokawa (The University of Tokyo) Dr. Marios Kurokawa (The University of Tokyo) Moduliqu ASKI I Microtion Revealed Inquisited Pressistation of pitidisks timogh Abersan PRCI-mediated Historia Microtion Revealed Inquisited Pressistation of pitidisks timogh Abersan PRCI-mediated Historia Microtion Revealed Inquisited Pressistation of pitidisks timogh Abersan PRCI-mediated Historia Microtion Revealed Inquisited Pressistation (University Spracker) Dr. Marios E. Kigerman (University Microtion Revealed Co., Ltd.)		Spoundi		
Dr. Mineo Kurokawa (The University of Takyo)			notes of Two Demetriylases for mistorie mon21, JMJD3 and UTA, In Normal Hematopolesis and Leukemogenesis	
D. Mines Kurokawa (The University of Tokyo) Substitute (ASI, Multitute Previous Treatment Hemotophication Caused by Descriptions (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)			Dr. Daniel Starczynowski (Cincinnati Children's Hospital Medical Center : University of Cincinnati, USA)	
Poster Viswing Post			Oncogenic Innate Immune Signaling in MDS and AML	
Poster Viswing Post			Dr. Minos Kurskaus (The University of Takya)	
Dr. Maria E. Figuerea (University of Miami Miller School of Medicine, USA)				
Epipemetic Deregulation in Aging and MDS				
Luncheon Seminar 1 (Co-Sponsored by Chugai Pharmaceutical Co., Ltd.)				
Luncheon Seminar 1 (Co-Sponsored by Chugal Pharmaceutical Co., Ltd.) Chair Or. Kenichi Ishizawa (Yamagata University)			Epigenetic Deregulation in Aging and MDS	
Chair Or. Kenichi Ishizawa (Yanagat Inhersity) Speaker Or. Ari Melnick (Weil Cornell Medicine, USA) Speaker Or. Ari Melnick (Weil Cornell Medicine, USA) Speaker Or. Ari Melnick (Weil Cornell Medicine, USA) Speaker Or. Shinauke Ida (Nagoya City University Oraduate School of Medical Sciences) Speaker Or. Irene M. Robbraid (Harvan Medical School: Steven and Michelle Kirsch Laboratory: Dana-Farber Cancer Institute, USA) Multiple Myeloma: Disease Mechanism and Treatment Strategy 12:50-13:55 SH-EHA Joint Session : Epigenetics of Myeloproliferative Neoplasm (MPN) Chair Or. Kinuko Mitani (Doklyo Medical University School of Medicine) Or. Shinyi Makao (Kanazawa University) Deregulated Polyconth Functions in the Pathogenesis of Myeloproliferative Neoplasms Or. Kazuya Shimoda (University) Deregulated Polyconth Functions in the Pathogenesis of Myeloproliferative Neoplasms Or. Rodock (Sodo University) Dr. Tony Green (University) of Milyazako) Dr. Tony Green (University) of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis of Phenotypes and Personalized Predictions Plenary Session 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair Or. Vashinobu Maeda (Okayama University) Hospital) Dr. Tony Green (University of Cambridge, UK) Speaker Or. Brian Huntry (University of Cambridge, UK) Or. Shinghi Myezaki (Magasadu University) Or. Shinghi Milyazaki (Magasadu University) Or. Shinghi Milyazaki (Magasadu University) Or. Shinghi Milyazaki (Magasadu University) Or. Shinghi Malignancies and Their Therapies, Clonal Hematopolesis TET2 Dioxygenese Activol in AML Devolopans Or. Shinghi Malignancies and Their Therapies, Clonal Hematopolesis Or. Norihiro Murakami (Nagoya University Hospital) Or. Shinghi Malignancies and Their Therapies, Clonal Hematopolesis Or. Norihiro Murakami (Nagoya Un	11:50~12:05		Break	
Speaker Dr. Ari Melnick (Weill Cornell Medicine, USA)	12:05~12:50	Luncheon S	Seminar 1 (Co-Sponsored by Chugai Pharmaceutical Co., Ltd.)	
Speaker Dr. Ari Melnick (Weill Cornell Medicine, USA)		Ol '	D. K. STALLEY CO. (New York, 1977)	
Biology of Folicular Lymphome				
Luncheon Seminar 2 (Co-Sponsored by Celegine K.K.) Chair Dr. Shimsuke Ilda (Nagoya City University Graduate School of Medical Sciences) Speaker Dr. Irane M. Ghobrial (Harvard Medical School: Steven and Michelle Kirsch Laboratory: Dana-Farber Cancer Institute, USA) Multiple Myeloma: Disease Mechanism and Treatment Strategy Poster Viewing JSH-EHA Joint Session: Epigenetics of Myeloproliferative Neoplasm (MPN) Chair Dr. Kimuko Mitani (Dokkyo Medical University) Dr. Shinji Nakao (Kanazawa University) Dr. Shinji Nakao (Kanazawa University) Dregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kanaya Shimoda (University Of Myazaki) The Role of Wild-Type and Mutant Calesticulin in Hematopolesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-Tone Pathogenesis of Phenotypes and Personalized Predictions Plenay Session 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair Dr. Yasushi Miyazaki (Nagasaki University) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Pathogenesis of University of Cambridge, UK) Dr. Brian Hunty (University of Cambridge, UK) Dr. Pathogenesis of University Hospital Dr. Presk Dr. Pathogenesis of University Hospital Dr. Presk Dr. Shight Chiba (University Hospital) Dr. Presk Michael (Elevity and Other Aspects of Hematopolesis Dr. Northiro Murakami (Nagoya University Hospital, Kyushu University of Tokyo) A Postive Peedback Loop of Mulant ASKL Land BAP1 Premotes Myeloid Leukemagenesis Dr. Shight Dr. Deedback Loop of Mulant ASKL Land BAP1 Premotes Myeloid Leukemagenesis Dr. Northiro Murakami (Nagoya Uni		Speaker		
Chair Dr. Shinsuke lida (Nagoya City University Graduate School of Medical Sciences)			Biology of Follicular Lymphoma	
Speaker Dr. Irene M. Ghobrial (Harvard Medical School: Steven and Michelle Kirsch Laboratory: Dana-Farber Cancer Institute, USA)		Luncheon S	Seminar 2 (Co-Sponsored by Celegine K.K.)	
Speaker Dr. Irene M. Ghobrial (Harvard Medical School: Steven and Michelle Kirsch Laboratory: Dana-Farber Cancer Institute, USA)		Chair	Dr. Shineuka lida (Nagova City University Graduata School of Madical Sciences)	
Nultiple Myelomar. Disease Mechanism and Treatment Strategy		-		
12:50-13:55 Poster Viewing JSH-EHA Joint Session : Epigenetics of Myeloproliferative Neoplasm (MPN) Chair Dr. Kimuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Speaker Dr. Atsushi Iwama (Chiba University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Myazaki) The Role of Wilki-Type and Mutant Calreticulin in Hematopolesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break Plenary Session 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K/Z as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TETZ Dioxygenese Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging Break Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Voshio Katayama (Kobe University Hospital) Dr. Voshio Katayama (Kobe University Hospital) Dr. Voshio Marayama (Kobe University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Tappel Sakoda (Kyushu University Hospital, Wyushu University Graduate School of Medical Sciences) Identification of a Novel Mar Pathway Activation Mechanism Medical Science, Identification of Medicial Sciences (Identification of Aniversity Hospital, Kyushu University Graduate School of Medicial		эреакег	· · · · · · · · · · · · · · · · · · ·	
Sh-EHA Joint Session : Epigenetics of Myeloproliferative Neoplasm (MPN)			Multiple Myelolila. Disease Methalishi alu Treathient Strategy	
Chair Chair Chis by Kinuko Mitani (Dokkyo Madical University) Speaker Dr. Atsushi Iwama (Chiba University) Dergulated Pelycomb functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopolesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break 15:55-17:35 Plenary Session 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML H3K27 as a Key Nexus for Transformation Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopolesic Stem Cell Aging Break Chair Dr. Assushi Hiraca (Kanazawa University Hospital) Dr. Yoshio Katayama (Kobe University Hospital) Dr. Yoshio Katayama (Kobe University Hospital) Dr. Shigeru Chiba (University of Gambridge, UK) Dr. Shigeru Chiba (University of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASAL1 and BAP1 Promotes Myeloid Leukemia Dr. Shigeru Chiba (Valvand Other Aspects of Hematopolesis Dr. Norinfor Murakami (Nagoy u University Graduate School of Medical Sciences) Identification of a Novel Wirt Pathway Activation Medichanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs				
Chair Chair Chis by Kinuko Mitani (Dokkyo Madical University) Speaker Dr. Atsushi Iwama (Chiba University) Dergulated Pelycomb functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopolesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break 15:55-17:35 Plenary Session 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML H3K27 as a Key Nexus for Transformation Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopolesic Stem Cell Aging Break Chair Dr. Assushi Hiraca (Kanazawa University Hospital) Dr. Yoshio Katayama (Kobe University Hospital) Dr. Yoshio Katayama (Kobe University Hospital) Dr. Shigeru Chiba (University of Cambridge, UK) Dr. Shigeru Chiba (University of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASAL1 and BAP1 Promotes Myeloid Leukemia Dr. Shigeru Chiba (Valvand Other Aspects of Hematopolesis Dr. Norinfor Murakami (Nagoy u University Graduate School of Medical Sciences) Identification of a Novel Wirt Pathway Activation Medichanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	12:50~13:55	Poster Viev	wing	
Chair Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Speaker Dr. Atsushi Iwama (Chiba University) Dregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University for James (University of Myazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University for James (University of Myazaki) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break Plenary Session 2: Epigenetic Ahonormalities of Hematological Malignancies; Basic and Clinical Studies Chair Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TEIZ/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntry (University of Toshinobu Maciejawski (Cleveland Clinic, USA) NaThe Maciejawski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging Break Chair Dr. Assushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Norihiro Murakami (Nagoy u University Graduate School of Medical Sciences) Integrated Molecular Profilling of Juvenile Myelomonocytic Leukemia Dr. Teppel Sakoda (Kyushu University Hospital) Dr. Propitio Katayama (Nagoy u University Graduate School of Medical Sciences) Identification of a Novel Wirt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	12:50~13:55	Poster Viev	wing	
Dr. Shinji Nakao (Kanazawa University) Speaker Dr. Atsushi Iwama (Chiba University) Dergulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Carleticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions 15:35–15:55 Plenary Session 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TETZ/MRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Hunty (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tawtush) TETZ Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolosin, TET2 Activity and Other Aspects of Hematopoiesis Chair Dr. Assushi Hiyasana (Kobe University Hospital) Speaker Dr. Vasushi Hiyasana (Kobe University Hospital) Dr. Voshio Katayama (Kobe University Hospital) Dr. Voshio Katayama (Kobe University Hospital) Dr. Norhion Murakamani (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppel Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medicial Sciences) Identification of a Novel Wnf Pathway Activation Mechanism Mediated by TiM-3/Gal-9/HCK Axis in Human AML-LSCs				
Speaker Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break		JSH-EHA Jo	oint Session : Epigenetics of Myeloproliferative Neoplasm (MPN)	
Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Cleriticulin in Hematopolesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break Plemary Session 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Speaker On. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/INRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Tasukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Clevaland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoletic Stem Cell Aging Break Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopolesis Chair Dr. Assushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Hospital, Kyushu University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Toppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wirt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs		JSH-EHA Jo	oint Session : Epigenetics of Myeloproliferative Neoplasm (MPN) Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine)	
Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University to Rospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions 15:35–15:35 Plenary Session 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair		JSH-EHA Jo	oint Session : Epigenetics of Myeloproliferative Neoplasm (MPN) Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine)	
The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break Plenary Session 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TETZ/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Taukuba) TETZ Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35-17:45 Break Prad Session: Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemia Dr. Teppei Sakoda (Kyushu University Graduate School of Medicine) Integrated Molecular Profiling of Juvenille Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Graduate School of Medicine Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs		JSH-EHA Jo	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University)	
Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break 15:55-17:55 Plenary Session 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35-17:45 Tr.45-18:15 Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Shigen Chiba (University Hospital) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shubei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Toppel Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medicine) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs		JSH-EHA Jo	Dr. Kinuko Mitani (Dokkyo Medical University) Dr. Atsushi Iwama (Chiba University)	
Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break 15:55-17:35 Plenary Session 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35-17:45 Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXLI and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs		JSH-EHA Jo	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms	
Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break		JSH-EHA Jo	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki)	
Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break		JSH-EHA Jo	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis	
15:35–17:35 Plenary Session 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:45–18:15 Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Asushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs		JSH-EHA Jo	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland)	
Plenary Session 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Chair Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hirroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntty (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35-17:45 Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Asushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs		JSH-EHA Jo	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms	
Chair Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35-17:45 Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs		JSH-EHA Jo	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK)	
Chair Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35-17:45 Tr.45-18:15 Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35	JSH-EHA Jo	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions	
Dr. Yasushi Miyazaki (Nagasaki University) Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:45-18:15 Oral Session: Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55	JSH-EHA Jo Chair Speaker	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break	
Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35-17:45 Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55	JSH-EHA Jo Chair Speaker	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies	
Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35–17:45 Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuheri Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55	JSH-EHA Jo Chair Speaker	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital)	
Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35~17:45 Break Oral Session: Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55	JSH-EHA Jo Chair Speaker Plenary Ses Chair	point Session : Epigenetics of Myeloproliferative Neoplasm (MPN) Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University)	
Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35~17:45 Break Oral Session: Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55	JSH-EHA Jo Chair Speaker Plenary Ses Chair	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break Ssion 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine)	
Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35~17:45 Terak Oral Session: Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55	JSH-EHA Jo Chair Speaker Plenary Ses Chair	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsuki Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TETZ/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity	
TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35~17:45 Dral Session: Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55	JSH-EHA Jo Chair Speaker Plenary Ses Chair	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK)	
Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35~17:45 Dral Session: Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55	JSH-EHA Jo Chair Speaker Plenary Ses Chair	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation	
NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging 17:35~17:45 Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University)	13:55~15:35 15:35~15:55	JSH-EHA Jo Chair Speaker Plenary Ses Chair	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calriculin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba)	
17:45~18:15 Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55	JSH-EHA Jo Chair Speaker Plenary Ses Chair	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntty (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development	
17:45-18:15 Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis Chair Dr. Atsushi Hirao (Kanazawa University)	13:55~15:35 15:35~15:55	JSH-EHA Jo Chair Speaker Plenary Ses Chair	Dir. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Disvygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA)	
Chair Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55 15:55~17:35	JSH-EHA Jo Chair Speaker Plenary Ses Chair	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Dr. Atsushi Iwama (Chiba University) Dr. Sayuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Razuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break Sision 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging	
Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASKL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55 15:55~17:35	JSH-EHA Jo Chair Speaker Plenary Ses Chair Speaker	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Razuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging	
Dr. Yoshio Katayama (Kobe University Hospital) Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASKL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55 15:55~17:35	JSH-EHA Jo Chair Speaker Plenary Ses Chair Speaker	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Razuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging	
Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55 15:55~17:35	JSH-EHA Jo Chair Speaker Plenary Ses Chair Speaker Oral Sessio	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break Break Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TETZ/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) IETZ Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging Break In: Hematological Malignancies and Their Therapies, Clonal Hematopoiesis	
A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55 15:55~17:35	JSH-EHA Jo Chair Speaker Plenary Ses Chair Speaker Oral Sessio	Dir. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Dr. Razuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University Hospital) Dr. Yasushi Miyazaki (Nagasaki University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in Mat. H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging Break Dr. Atsushi Hirao (Kanazawa University)	
Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55 15:55~17:35	JSH-EHA Jo Chair Speaker Plenary Ses Chair Speaker Oral Sessio Chair	Dir. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Dr. Atsushi Iwama (Chiba University) Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoiesis Dr. Atsushi Hirao (Kanazawa University) Dr. Hisushi Hirao (Kanazawa University) Dr. Atsushi Hirao (Kanazawa University) Dr. Yashio Katayama (Kobe University Hospital)	
Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55 15:55~17:35	JSH-EHA Jo Chair Speaker Plenary Ses Chair Speaker Oral Sessio Chair	Dir. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyashi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntty (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging Break Dr. Kusushi Hirao (Kanazawa University) Dr. Stuhei Asada (The Institute of Medical Science, The University of Tokyo)	
Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55 15:55~17:35	JSH-EHA Jo Chair Speaker Plenary Ses Chair Speaker Oral Sessio Chair	Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break ssion 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyeshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dystunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging Break Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Dr. Or. Shigeru Chiba (University of Tsukuba) Tera Chroshio (University of Tsukuba) Dr. Shigeru Chiba (University of University) Dr. Yoshio Katayama (Kobe University Hospital) Dr. Shigeru Chiba (University of University) Dr. Yoshio Katayama (Kobe University Hospital) Dr. Shigeru Chiba (University of University) Dr. Yoshio Katayama (Kobe University Hospital)	
Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs	13:55~15:35 15:35~15:55 15:55~17:35	JSH-EHA Jo Chair Speaker Plenary Ses Chair Speaker Oral Sessio Chair	Dir. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break Ssion 2: Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TETZ/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: HSK27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Cilinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging Break Dr. Atsushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine)	
	13:55~15:35 15:35~15:55 15:55~17:35	JSH-EHA Jo Chair Speaker Plenary Ses Chair Speaker Oral Sessio Chair	Dirit Session : Epigenetics of Myeloproliferative Nooplasm (MPN) Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Shinji Nakao (Kanazawa University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) Dr. Kazuya Shimoda (University of Miyazaki) Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tong Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break Ston 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yasushi Miyazaki (Nagasaki University) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML; H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Tsukuba) IET2 Dioxygenises Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging Break Break Dr. Katushi Hirao (Kanazawa University) Dr. Shigher Asayama (Kobe University) Aspital) Dr. Shigher Asayama (Kobe University) Hospital) Dr. Shohio Katushi Hirao (Kanazawa University) Dr. Poshio Katushi Hirao (Kanazawa University) Dr. Shigher Asayama (Kobe University) Hospital) Dr. Shigher Asayama (Kobe Univer	
Welcome Reception	13:55~15:35 15:35~15:55 15:55~17:35	JSH-EHA Jo Chair Speaker Plenary Ses Chair Speaker Oral Sessio Chair	Dirt. Session : Epigenetics of Myeloproliferative Neoplasm (MPN) Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) Dr. Shinji Nakao (Kanazawa University) Dr. Astushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopolesis Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions Break Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Yoshinobu Maeda (Okayama University Hospital) Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TETZ/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity Dr. Brian Hursty (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation Dr. Shigeru Chiba (University of Cambridge, UK) Epigenesiase Activity in AML Development Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD- Metabolism, TET2 Activity and Other Aspects of Hematopoiesis Dr. Assushi Hirao (Kanazawa University) Dr. Yoshio Katayama (Kobe University Hospital) Dr. Shiel Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Toppei Sakoda (Kyushu University Hospital, Wushu University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Dr. Toppei Sakoda (Kyushu University Hospital, Wushu University Graduate School of Medical Sciences)	

	INIOTHING SE	nminor 1 (Co Spanograd by Finai Co 1 td.)		
L	Ü	Morning Seminar 1 (Co-Sponsored by Eisai Co., Ltd.)		
	Chair	Dr. Akifumi Takaori-Kondo (Kyoto University)		
	Speaker	Dr. Jonathan D. Licht (University of Florida Health Cancer Centerm, USA)		
_		Epigenetic Deregulation in Blood And Other Malignancies - Focus on EZH2-		
	Morning Seminar 2 (Co-Sponsored by SymBio Pharmaceuticals Limited. /Onconova Therapeutics, Inc.)			
-	Chair	Dr. Hideki Muramatsu (Nagoya University Graduate School of Medicine)		
ľ	Speaker	Dr. Lewis R Silverman (The Mount Sinai Hospital and School of Medicine, USA) Rigosertib-Strategies in MDS and Pediatric Rasopathies		
8:45~8:50		Break		
8:50~10:10	Plenary Session 3 : Clinical Studies and New Epigenetic Therapies for Hematological Malignancies			
	Chair Dr. Itaru Matsumura (Kindai University)			
		Dr. Norio Komatsu (Juntendo University)		
-	Speaker			
ľ	Speaker	Dr. Ravi Majeti (Stanford University, USA) Epigenetic Dysregulation in Human AML Stem Cells		
		Dr. Issay Kitabayashi (National Cancer Center Research Institute) Cancer Stem Cell-Targeted Therapy for Hematological Malignancy Based on Dual Inhibition of EZH1/EZH2		
		Dr. Jonathan D. Licht (University of Florida Health Cancer Center, USA) Deregulation and Oncogenic Functions of the NSD2/MMSET Histone Methyl Transferase in Hematological Malignancies		
10:10~10:20		Break		
10.00 10.00				
10.20~12.00	JSH-ASH Joint Session : Epigenetics of Hematological Malignancies			
•	Chair	Dr. Koichi Akashi (Kyushu University)		
		Dr. Hideaki Nakajima (Yokohama City University Graduate School of Medicine)		
	Speaker	Dr. Omar Abdel-Wahab (Memorial Sloan Kettering Cancer Center, USA)		
		Coordinated Alterations in RNA Splicing and Epigenetic Regulation Drive Leukemogenesis		
		Dr. Toshio Kitamura (The Institute of Medical Science, University of Tokyo)		
		EZH2 Mutations Induce MDS-like Symptoms in Mouse BMT Models via Overexpression of ABC-G2 and Inhibition of Bone Formation		
		Dr. Seishi Ogawa (Kyoto University)		
		Stag2 Regulates Hematopoietic Differentiation and Self-Renewal		
		Dr. Margaret Goodell (Baylor College of Medicine, USA)		
		DNA Methyltransferase 3A in Normal and Malignant Hematopoiesis		
12:00~12:15	Break			
12:15~13:00	Luncheon	Seminar 3 (Co-Sponsored by Nippon Shinyaku Co.,Ltd.)		
	Chair	Dr. Hideaki Nakajima (Yokohama City University Graduate School of Medicine)		
	Speaker	Dr. Daniel Starczynowski (Cincinnati Children's Hospital Medical Center : University of Cincinnati, USA)		
Ĺ	Орешкет	Novel Therapeutic Targets in Myeloid Malignancies		
	Luncheon Seminar 4 (Co-Sponsored by Bristol-Myers Squibb K.K.)			
	Chair	Dr. Koichi Akashi (Kyushu University)		
	Speaker	Dr. Brian Huntly (University of Cambridge, UK)		
,	Сроило	Leukaemia Stem Cells: Root of Persistence and Transformation and True Therapeutic Target in CML		
13:00~13:10		Break		
13:10~14:10	Sweets Seminar Special Lecture 1 · 2 : Epigenetic Aspects of Hematological Malignancies and Their Therapies			
	Chair	Dr. Yuzuru Kanakura (Osaka University Graduate School of Medicine)		
		Dr. Masahiro Kizaki (Saitama Medical Center, Saitama Medical University)		
		Dr. Raphael Itzykson (Hopital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris Diderot University, France)		
<u>, </u>	Speaker			
- !	Speaker	Recent Insight on the Clinical Use of Hypomethylating Agents		
:	Speaker			
:	Speaker	Recent Insight on the Clinical Use of Hypomethylating Agents		